QUICK SEARCH:   [advanced] Author: Keyword(s):
Home     Help     Feedback     Subscriptions     Archive     Search     Table of Contents

First published online 3 April 2007
doi: 10.1242/jcs.03438

This Article Figures Only Full Text Full Text (PDF) All Versions of this Article: jcs.03438v1 120/9/1615    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by van Tijn, P. Articles by Hol, E. M. Search for Related Content PubMed PubMed Citation Articles by van Tijn, P. Articles by Hol, E. M.

Dose-dependent inhibition of proteasome activity by a mutant ubiquitin associated with neurodegenerative disease

Paula van Tijn^1,*, Femke M. S. de Vrij^1,*,, Karianne G. Schuurman¹, Nico P. Dantuma², David F. Fischer^1,, Fred W. van Leeuwen^1,¶ and Elly M. Hol^1,**

¹ Netherlands Institute for Neuroscience, Meibergdreef 47, 1105 BA Amsterdam, The Netherlands
² Department of Cell and Molecular Biology, The Medical Nobel Institute, Karolinska Institutet, Box 285, SE-17177 Stockholm, Sweden

^** Author for correspondence (e-mail: e.hol{at}nin.knaw.nl)

Accepted 21 February 2007

The ubiquitin-proteasome system is the main regulated intracellular proteolytic pathway. Increasing evidence implicates impairment of this system in the pathogenesis of diseases with ubiquitin-positive pathology. A mutant ubiquitin, UBB⁺¹, accumulates in the pathological hallmarks of tauopathies, including Alzheimer's disease, polyglutamine diseases, liver disease and muscle disease and serves as an endogenous reporter for proteasomal dysfunction in these diseases. UBB⁺¹ is a substrate for proteasomal degradation, however it can also inhibit the proteasome. Here, we show that UBB⁺¹ properties shift from substrate to inhibitor in a dose-dependent manner in cell culture using an inducible UBB⁺¹ expression system. At low expression levels, UBB⁺¹ was efficiently degraded by the proteasome. At high levels, the proteasome failed to degrade UBB⁺¹, causing its accumulation, which subsequently induced a reversible functional impairment of the ubiquitin-proteasome system. Also in brain slice cultures, UBB⁺¹ accumulation and concomitant proteasome inhibition was only induced at high expression levels. Our findings show that by varying UBB⁺¹ expression levels, the dual proteasome substrate and inhibitory properties can be optimally used to serve as a research tool to study the ubiquitin-proteasome system and to further elucidate the role of aberrations of this pathway in disease.

Key words: Ubiquitin, Ubiquitin-proteasome system, Neurodegeneration, Alzheimer's disease, Protein aggregation, Protein degradation

This article has been cited by other articles:

				S. Song, H. Lee, T.-I. Kam, M. L. Tai, J.-Y. Lee, J.-Y. Noh, S. M. Shim, S. J. Seo, Y.-Y. Kong, T. Nakagawa, et al. E2-25K/Hip-2 regulates caspase-12 in ER stress-mediated A{beta} neurotoxicity J. Cell Biol., August 25, 2008; 182(4): 675 - 684. [Abstract] [Full Text] [PDF]

				I. Ferrer, G. Santpere, and F. W. van Leeuwen Argyrophilic grain disease Brain, June 1, 2008; 131(6): 1416 - 1432. [Abstract] [Full Text] [PDF]